AMYRIAD IS ADDRESSING THE CORE SYMPTOMS OF AD: COGNITION AND GLOBAL FUNCTION

We are developing two series of small, synthetic molecules. Each series enhances neurotransmission in a different way.

Our 100 Series lead compound, AD101, demonstrated statistically significant improvement in both core symptoms of AD in Placebo-controlled, Double-blind, Phase 2 Proof of Concept Trials. Efficacy was accompanied by a superb profile of safety and tolerability that was not distinguishable from that of the placebo-treated cohort.

OUR PIPELINE

100 SERIES – SELECTIVE CaV3.1 AND CaV3.3 T-TYPE

CALCIUM CHANNEL ANTAGONISTS

AD 101

AD 102

AD 103

AD 104

AD 102 AD 103 AD 104

200 SERIES – CALCIUM / CALMODULIN-DEPENDENT

PROTEIN KINASE II

Three

candidates

Three candidates

400 SERIES – NERVE GROWTH FACTOR/ATP

CITRATE LYASE ENHANCERS

AD 401